Skip to main content

ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.

Publication ,  Journal Article
Akin, EA; Wallner, PE; Alexander, S; Barry, P; Colletti, PM; Deville, C; Kuo, PH; Kishan, A; Morris, Z; Mulugeta, PG; Pandit-Tasker, N ...
Published in: Am J Clin Oncol
August 25, 2025

OBJECTIVES: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The document represents an update of the radium-223 therapy practice parameter developed by the societies in 2019. METHODS: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, in collaboration with the ACNM, the ARS, and the SNMMI. Reports available since the publication of the initial document in 2019 were collected and reviewed. RESULTS: Since the publication of the initial radium-223 practice parameter in 2019, there has been significant investigation of the agent in the management of numerous metastatic cancer sites, in addition to additional studies of its use in metastatic hormone-resistant prostate cancer. This updated document considers physical properties of the agent, current and investigative indications, qualifications and responsibilities of personnel, specifications of the evaluation exam and treatment, the therapeutic use of unsealed radiopharmaceutical sources, radiation safety, and quality control. CONCLUSIONS: This updated practice parameter is intended to guide appropriately trained and credentialed physicians performing therapy with radium-223 dichloride. All aspects of patient and radioisotope management are considered, as are current indications and ongoing investigations.

Duke Scholars

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

August 25, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1105 Dentistry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Akin, E. A., Wallner, P. E., Alexander, S., Barry, P., Colletti, P. M., Deville, C., … Schechter, N. R. (2025). ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride. Am J Clin Oncol. https://doi.org/10.1097/COC.0000000000001245
Akin, Esma A., Paul E. Wallner, Sindu Alexander, Parul Barry, Patrick M. Colletti, Curtiland Deville, Phillip H. Kuo, et al. “ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.Am J Clin Oncol, August 25, 2025. https://doi.org/10.1097/COC.0000000000001245.
Akin EA, Wallner PE, Alexander S, Barry P, Colletti PM, Deville C, et al. ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride. Am J Clin Oncol. 2025 Aug 25;
Akin, Esma A., et al. “ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.Am J Clin Oncol, Aug. 2025. Pubmed, doi:10.1097/COC.0000000000001245.
Akin EA, Wallner PE, Alexander S, Barry P, Colletti PM, Deville C, Kuo PH, Kishan A, Morris Z, Mulugeta PG, Pandit-Tasker N, Rabatic BM, Saboury B, Sharma N, Ghesani MV, Subramaniam RM, Small W, Schechter NR. ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride. Am J Clin Oncol. 2025 Aug 25;

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

August 25, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1105 Dentistry